Home/Pipeline/ASO for Lung Cancer

ASO for Lung Cancer

Lung Cancer

Pre-clinicalActive

Key Facts

Indication

Lung Cancer

Phase

Pre-clinical

Status

Active

Company

Carnation Therapeutics

About Carnation Therapeutics

Carnation Therapeutics is an early-stage biotech leveraging antisense oligonucleotide technology to target cancer at the genetic level. Founded in 2022, the company is in the preclinical research phase, developing therapies for high-need oncology indications such as lung cancer and melanoma. Operating as a private, pre-revenue entity, it aims to grow into a leading innovator by modulating protein expression through mRNA interaction, offering a novel approach to difficult-to-treat cancers.

View full company profile

Therapeutic Areas

Oncology

Other Lung Cancer Drugs

Drug	Company	Phase	Status
OncoStrong™	Lamark Biotech	Preclinical	Active
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active